Across 55 unique European CTIS-authorized lupus Phase II–III trials, 29 trials listed at least one CRO or specialist trial-support vendor, equal to 52.7%. IQVIA was the most active provider, appearing in 21 of 55 trials overall and 21 of 29 CRO-supported trials. CRO need was highest when trials crossed operational scale thresholds: 23 of 27 trials with more than 15 sites used CRO support, and all 3 trials with more than 12 countries used CRO support.
IQVIA appeared in 21 of 29 CRO-supported trials, or 72.4%. Parexel followed with 11 of 29 CRO-supported trials, while PPD / Thermo Fisher appeared in 10 of 29. The CRO market is therefore concentrated at the top, but most large lupus trials use multi-vendor operating models rather than a single outsourced partner.
IQVIA is the dominant CRO signal in this lupus dataset, but Parexel, PPD / Thermo Fisher, ICON, and Syneos each appeared in at least 9 CRO-supported trials. This suggests the addressable market is not only full-service CRO management; it also includes central lab, IRT, eCOA, imaging, recruitment, and CTIS submission support.
CRO support was uncommon in very small trials: only 4 of 19 trials with 30 or fewer target participants used CRO support. By contrast, 12 of 14 trials with more than 250 target participants used CRO support, and 23 of 27 trials with more than 15 European sites used CRO support.
The strongest CRO-buying trigger is operational scale, not phase alone. A practical threshold for lupus is 4 or more European countries, more than 15 sites, more than 100 planned participants, or more than 31 European participants.
CRO support appeared in 5 of 6 cutaneous lupus erythematosus trials and 14 of 20 systemic lupus erythematosus trials. Lupus nephritis also showed clear outsourcing demand, with CRO support in 4 of 7 lupus nephritis-only trials and 5 of 10 SLE plus lupus nephritis trials.
| Indication group | CRO / total | Share |
|---|---|---|
| Cutaneous lupus erythematosus | 5 / 6 | 83.3% |
| Systemic lupus erythematosus | 14 / 20 | 70.0% |
| Lupus nephritis | 4 / 7 | 57.1% |
| SLE with lupus nephritis | 5 / 10 | 50.0% |
| Mixed lupus / adjacent autoimmune | 1 / 12 | 8.3% |
Commercial outsourcing demand is strongest where lupus trials are indication-specific and operationally mature. Mixed autoimmune umbrella studies had lower CRO use, while cutaneous lupus, systemic lupus erythematosus, and lupus nephritis generated the highest specialist support demand.
Laboratory, sample, and biomarker work appeared in 30 of 55 trials, the highest outsourced function category. eCOA, EDC, IRT, and digital systems appeared in 26 of 55 trials. Regulatory, CTIS, and EU submission support appeared in 16 of 55 trials and 15 of 29 CRO-supported trials.
Lupus outsourcing is heavily operational and evidence-generation oriented: labs, sample handling, biomarkers, eCOA/EDC/IRT systems, rater training, imaging, recruitment, and CTIS/EU submission support form the core vendor demand stack.
Among CRO-supported trials, Spain appeared in 24 trials and accounted for 166 sites. Poland appeared in 21 trials and carried the largest participant allocation among the top countries, with 495 participants. CTIS Part II coordination was therefore concentrated in repeat high-volume EU countries rather than spread evenly across Europe.
| Country | Trials | Sites | Participants | Median CTIS Part II days |
|---|---|---|---|---|
| Spain | 24 | 166 | 359 | 276.5 |
| Poland | 21 | 143 | 495 | 298.0 |
| France | 19 | 127 | 233 | 107.0 |
| Germany | 18 | 102 | 270 | 260.5 |
| Italy | 16 | 89 | 201 | 315.0 |
| Bulgaria | 14 | 82 | 310 | 241.0 |
| Romania | 14 | 52 | 192 | 333.0 |
For CRO targeting, Spain, Poland, France, Germany, Italy, Bulgaria, and Romania are the strongest operational geographies. These countries combine repeat lupus trial activity, substantial site burden, participant allocation, and CTIS Part II coordination workload.
Three additional questions are answerable with the same CTIS data: which sponsor types outsource, whether randomized trials outsource more often, and how CTIS timelines differ in CRO-supported trials. Pharma sponsors accounted for all CRO-supported trials in the cohort.
The best commercial targeting signals are pharma sponsorship, randomized controlled design, multi-country CTIS operations, and high country-level Part II workload. These signals identify trials where CROs are needed for practical execution, not only protocol design.
CRO-supported means at least one CRO or specialist operational trial vendor was listed for the trial. CTIS means Clinical Trials Information System. EU Part II refers to country-specific clinical trial assessment elements such as local site, participant, ethics, and national authorization components. eCOA means electronic clinical outcome assessment; EDC means electronic data capture; IRT means interactive response technology; PRO means patient-reported outcome; PV means pharmacovigilance.